Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 2/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963389 | 1.00 | TK1 (0.41) | TK1CTSKCYP2C19HIF1AKDM4E | |
| SCHEMBL10776041 | 0.84 | TK1 (0.44) | TK1CTSKALDH1A1LMNA | |
| SCHEMBL9175373 | 0.84 | TK1 (0.44) | TK1CTSKALDH1A1LMNA | |
| SCHEMBL10433900 | 0.83 | TK1 (0.43) | TK1CTSKCYP2C19HIF1ADUT | |
| SCHEMBL9178224 | 0.83 | TK1 (0.43) | TK1CTSKCYP2C19HIF1ADUT | |
| SCHEMBL3833368 | 0.83 | TK1 (0.41) | TK1CTSKCYP2C19HIF1AKDM4E | |
| SCHEMBL5350935 | 0.83 | TK1 (0.41) | TK1CTSKCYP2C19HIF1AKDM4E | |
| SCHEMBL5354077 | 0.79 | TK1 (0.45) | TK1CTSKALDH1A1ADRB2ADRB1 | |
| SCHEMBL3837132 | 0.79 | TK1 (0.45) | TK1CTSKALDH1A1ADRB2ADRB1 | |
| SCHEMBL2344498 | 0.79 | ADRB2 (0.58) | HIF1AALDH1A1TDP1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7301046-B2 | Boronate esters | BIOCON LIMITED (IN) | 2007-11-27 | — | — | US | disclosed |
| US-20050154213-A1 | Novel boronate esters | BIOCON LIMITED (IN) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154213-A1 | Novel boronate esters | HMGCR, BLVRB, COASY | TK1 1388/4885CTSK 1041/4885CYP2C19 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.